Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vaccination timing after rituximab in non-Hodgkin lymphoma remission
NL-OMON39920Not yet recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Mar 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Randomised, open-label trial of Prevnar 13, haemophilus influenzae type b vaccine, 23-valent pneumococcal polysaccharide vaccine and rituximab in Pneumococcal pneumonia (PP) and Haemophilus influenzae type b disease (Hib) (2 arms), sponsored by St. Antonius Ziekenhuis. Primary endpoint: Antibody titres against Streptococcus pneumoniae and Haemophilus influenzae type b. Planned start Mar 2014; status: not yet recruiting.
02
Drugs
Prevnar 13haemophilus influenzae type b vaccine23-valent pneumococcal polysaccharide vaccinerituximab
03
Conditions
Pneumococcal pneumonia (PP)Haemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on NL-OMON39920.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39920.